Medical oncologists' perspectives of the Veterans Affairs National Precision Oncology Program.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Background: To support the rising need for testing and to standardize tumor DNA sequencing practices within the U.S. Department of Veterans Affairs (VA)'s Veterans Health Administration (VHA), the National Precision Oncology Program (NPOP) was launched in 2016. We sought to assess oncologists' practices, concerns, and perceptions regarding Next-Generation Sequencing (NGS) and the NPOP.
      Materials and Methods: Using a purposive total sampling approach, oncologists who had previously ordered NGS for at least one tumor sample through the NPOP were invited to participate in semi-structured interviews. Questions assessed the following: expectations for the NPOP, procedural requirements, applicability of testing results, and the summative utility of the NPOP. Interviews were assessed using an open coding approach. Thematic analysis was conducted to evaluate the completed codebook. Themes were defined deductively by reviewing the direct responses to interview questions as well as inductively by identifying emerging patterns of data.
      Results: Of the 105 medical oncologists who were invited to participate, 20 (19%) were interviewed from 19 different VA medical centers in 14 states. Five recurrent themes were observed: (1) Educational Efforts Regarding Tumor DNA Sequencing Should be Undertaken, (2) Pathology Departments Share a Critical Role in Facilitating Test Completion, (3) Tumor DNA Sequencing via NGS Serves as the Most Comprehensive Testing Modality within Precision Oncology, (4) The Availability of the NPOP Has Expanded Options for Select Patients, and (5) The Completion of Tumor DNA Sequencing through the NPOP Could Help Improve Research Efforts within VHA Oncology Practices.
      Conclusion: Medical oncologists believe that the availability of tumor DNA sequencing through the NPOP could potentially lead to an improvement in outcomes for veterans with metastatic solid tumors. Efforts should be directed toward improving oncologists' understanding of sequencing, strengthening collaborative relationships between oncologists and pathologists, and assessing the role of comprehensive NGS panels within the battery of precision tests.
      Competing Interests: In regard to potential competing interests, authors JLS, VM, DW, and GPJ are employed by IBM Watson Health. In addition, author HGS was previously employed by IBM Watson Health and author VLP is a consultant for IBM Watson Health. As mentioned, the commercial interest did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
    • References:
      J Genet Couns. 2017 Aug;26(4):878-886. (PMID: 28091859)
      Arch Pathol Lab Med. 2017 Dec;141(12):1679-1685. (PMID: 29028368)
      Pediatr Blood Cancer. 2016 Aug;63(8):1368-74. (PMID: 27082517)
      J Genet Couns. 2016 Apr;25(2):218-27. (PMID: 26259529)
      Cancer. 2017 Jun 15;123(12):2352-2359. (PMID: 28192596)
      Oncologist. 2019 Oct;24(10):1287-1290. (PMID: 31366725)
      J Pers Med. 2018 Sep 17;8(3):. (PMID: 30227640)
      Clin Lung Cancer. 2017 Jul;18(4):401-409. (PMID: 28038980)
      JCO Precis Oncol. 2017;2017:. (PMID: 30320296)
      Arch Pathol Lab Med. 2014 Apr;138(4):498-504. (PMID: 24678680)
      Fam Cancer. 2018 Apr;17(2):309-316. (PMID: 28852913)
      Lung Cancer. 2018 Feb;116:25-29. (PMID: 29413047)
      Clin Cancer Res. 2018 Jun 15;24(12):2719-2731. (PMID: 29420224)
      J Oncol Pract. 2019 Dec;15(12):e1028-e1034. (PMID: 31373836)
      Am Soc Clin Oncol Educ Book. 2015;:e175-82. (PMID: 25993170)
      Psychooncology. 2018 Apr;27(4):1327-1333. (PMID: 29471587)
      JAMA. 2017 Sep 5;318(9):825-835. (PMID: 28873162)
      Am Soc Clin Oncol Educ Book. 2017;37:160-169. (PMID: 28561651)
      Fed Pract. 2018 Feb;35(Suppl 1):S53-S57. (PMID: 30766390)
      Clin Genet. 2015 Dec;88(6):565-72. (PMID: 25523111)
      J Exp Clin Cancer Res. 2019 Apr 11;38(1):156. (PMID: 30975211)
      J Clin Oncol. 2014 May 1;32(13):1317-23. (PMID: 24663044)
      NPJ Precis Oncol. 2018 Apr 16;2:11. (PMID: 30202789)
    • Publication Date:
      Date Created: 20200725 Date Completed: 20200915 Latest Revision: 20200915
    • Publication Date:
      20240104
    • Accession Number:
      PMC7380614
    • Accession Number:
      10.1371/journal.pone.0235861
    • Accession Number:
      32706774